Traws Pharma Inc (TRAW) Stock Price, Quote & News - Mboum

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3680

Fax: 267 759 3681

Website: www.trawspharma.com

Address:

12 Penns Trail, Newtown, United States

Twitties00 Dec. 5 at 1:12 PM

$TRAW Assuming everyone knows the H5N1 antiviral is also for seasonal flu and that this flu season is forecast to be the worst in a very long time. And did you hear about the COVID antiviral?… 💰💰💰🛸

0 · Reply

Twitties00 Dec. 5 at 12:55 PM

$TRAW 🇺🇸💎🔥

0 · Reply

Twitties00 Dec. 5 at 11:49 AM

$TRAW 🇺🇸💎🔥

0 · Reply

Otherseal Dec. 5 at 12:16 AM

$TRAW interesting market action

0 · Reply

Twitties00 Dec. 4 at 8:31 PM

$TRAW 🇺🇸💎🔥

0 · Reply

Schube1255 Dec. 4 at 8:07 PM

$TRAW $LAES $FERN $SMX 💰💰💰

0 · Reply

Dwarn2021 Dec. 3 at 7:37 PM

1 · Reply

Dwarn2021 Dec. 3 at 2:56 PM

$TRAW So glad i kept buying on every dip for the past 8 months. This is extremely bullish news!

2 · Reply

JarvisFlow Dec. 3 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Traws Pharma ( $TRAW ), setting the rating to Buy with a target price of 8.

2 · Reply

janon10 Dec. 3 at 12:42 AM

$TRAW And suddenly.. we sit again at 27 RSI.. You know what happened last three times we visited <30 RSI?. I know, and i posted every single times. another-higher-low. AS long as 2.07 isnt lost with high vol, bullish structure remains intact. Lets go bulls, long way to valhalla and wont gonna be easy!!

1 · Reply

Latest News on TRAW

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 30, 2025, 12:00 PM EDT - 5 weeks ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 22, 2025, 6:40 PM EDT - 6 weeks ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 3 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 1:14 PM EDT - 4 months ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 5 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 6 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 6 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 7 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 8 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 8 months ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 9 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 9 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 10 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 11 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 11 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Twitties00 Dec. 5 at 1:12 PM

$TRAW Assuming everyone knows the H5N1 antiviral is also for seasonal flu and that this flu season is forecast to be the worst in a very long time. And did you hear about the COVID antiviral?… 💰💰💰🛸

0 · Reply

Twitties00 Dec. 5 at 12:55 PM

$TRAW 🇺🇸💎🔥

0 · Reply

Twitties00 Dec. 5 at 11:49 AM

$TRAW 🇺🇸💎🔥

0 · Reply

Otherseal Dec. 5 at 12:16 AM

$TRAW interesting market action

0 · Reply

Twitties00 Dec. 4 at 8:31 PM

$TRAW 🇺🇸💎🔥

0 · Reply

Schube1255 Dec. 4 at 8:07 PM

$TRAW $LAES $FERN $SMX 💰💰💰

0 · Reply

Dwarn2021 Dec. 3 at 7:37 PM

1 · Reply

Dwarn2021 Dec. 3 at 2:56 PM

$TRAW So glad i kept buying on every dip for the past 8 months. This is extremely bullish news!

2 · Reply

JarvisFlow Dec. 3 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Traws Pharma ( $TRAW ), setting the rating to Buy with a target price of 8.

2 · Reply

janon10 Dec. 3 at 12:42 AM

$TRAW And suddenly.. we sit again at 27 RSI.. You know what happened last three times we visited <30 RSI?. I know, and i posted every single times. another-higher-low. AS long as 2.07 isnt lost with high vol, bullish structure remains intact. Lets go bulls, long way to valhalla and wont gonna be easy!!

1 · Reply

Dwarn2021 Dec. 2 at 8:00 PM

$TRAW i am picking up shares here that others are selling.

0 · Reply

Otherseal Dec. 2 at 7:35 PM

$TRAW hopefully not a negative release of the phase 2 studies

0 · Reply

Schube1255 Dec. 2 at 1:47 PM

$TRAW volume 1

0 · Reply

Twitties00 Dec. 1 at 7:56 PM

$TRAW 🇺🇸💎🔥

0 · Reply

Schube1255 Dec. 1 at 3:13 PM

$TRAW $FERN $LAES

0 · Reply

Titi_Valk Dec. 1 at 11:23 AM

$TRAW 👀 https://x.com/COVID19_disease/status/1995165302594957608?t=4oA46YGljI74p9SyucGftQ&s=19

0 · Reply

sergyo11 Dec. 1 at 5:47 AM

$TRAW this week we can se 3- 3,5 if all is good $TRAW

0 · Reply

Dwarn2021 Nov. 30 at 4:17 PM

$TRAW we are going to need every tool we can get against this.

0 · Reply

Twitties00 Nov. 29 at 7:02 PM

$TRAW 💰💰💰

0 · Reply

Razor_BTC_F150 Nov. 28 at 6:11 PM

$TRAW I’m back even 🙂👍🏽

0 · Reply

sergyo11 Nov. 28 at 5:13 PM

$TRAW go to 4!

0 · Reply

Titi_Valk Nov. 28 at 4:47 AM

$TRAW hummm... tivoxavir marboxil is comming!!!

0 · Reply